Gilead Sciences stock slips 0.64% to EUR 153.10 premarket
Published on 11/13/2026 at 08:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSGilead targets major diseases
- Gilead develops medicines across virology, oncology and inflammation.
- The company says it offers more than 25 medicines globally.
- Its pipeline includes 49 clinical programs across the three therapeutic areas.
Gilead Sciences stock traded at EUR 153.10 on Lang & Schwarz at 07:58 CET on Friday, November 13, 2026, 0.64 percent below the Xetra close of Thursday, November 12, 2026 at EUR 154.08.
The move puts the U.S. biotechnology company below the previous Xetra session's closing level before the regular European market opens. The price signal points to a cautious start for the stock, while the broader investment case remains tied to drug sales, pipeline progress and clinical execution.
Pipeline remains central to outlook
Gilead says on its corporate website that it focuses on virology, oncology and inflammation. The company also highlights more than 25 medicines offered globally and 49 clinical programs across those therapeutic areas.
For investors, the pipeline provides the main route to offset concentration around established products and to support longer-term growth. Clinical outcomes, regulatory decisions and commercial uptake can therefore have a greater impact on the shares than a single premarket indication.
The broader U.S. market context is covered in the S&P 500 market report.
More company-specific coverage is available in More news and analyses on Gilead Sciences stock.
